OCUGEN INC. news, videos and press releases - Page 5
For more news please use our advanced search feature.
OCUGEN INC. - More news...
OCUGEN INC. - More news...
- Ocugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
- Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference
- Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer
- Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
- Ocugen Provides Business Update & Second Quarter 2022 Financial Results
- Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results
- Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases
- Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’
- Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy
- Ocugen, Inc. to Present at BIO International Convention 2022
- Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition
- Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference
- Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)
- Ocugen Provides Business Update and First Quarter 2022 Financial Results
- Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results
- Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
- Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial
- Ocugen, Inc. to Present at NobleCon18
- Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America
- Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)
- Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration
- Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors
- Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance
- Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Ocugen, Inc. to Present at the 34th Annual ROTH Conference
- Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request
- Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results
- Ocugen, Inc. Announces Pricing of $53.5 Million Public Offering of Common Stock
- Ocugen, Inc. Announces Proposed Public Offering of Common Stock
- Ocugen to Host Conference Call on Friday, February 25 at 8:30 a.m. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update
